A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma

Clinical trial NCT05256472 · COMPLETED

Trial details

NCT number: NCT05256472
Sponsor: Akeso
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Renal Cell Carcinoma First-line Treatment

Start date: 2023-07-06
Primary completion: 2025-12-31
Enrollment: 28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.